Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns

BMC Infectious Diseases

Table 2 Independent variables associated with viral load pattern (TND, RV, LLV)

Variables	OR^a	95% CI	pV
Gender
Male	Ref.	−	−
Female	1.22	0.57–2.61	0.614
Age (years, continuous)	0.98	0.94–1.02	0.377
Therapy regimen
INI	Ref.	−	−
NRTIs + NNRTIs	0.11	0.03–0.43	0.001
NRTIs + PIs	0.26	0.08–0.88	0.030
Others	0.22	0.05–0.95	0.043
Duration of therapy (years, continuous)	1.08	0.94–1.23	0.267
Stage of disease
A1-A3	Ref.	−	−
B1-B3	0.87	0.27–2.81	0.818
C1-C3	1.07	0.48–2.35	0.872
Years from testing (years, continuous)	0.96	0.85–1.08	0.494
HBV
Negative	Ref.	−	−
Positive	2.25	0.67–7.59	0.191
HCV
Negative	Ref.	−	−
Positive	0.77	0.23–2.54	0.664
sCD14 (continuous)	1.66	1.32–2.08	<0.001
IL-6 (continuous)	0.99	0.96–1.02	0.386
TNF-α (continuous)	1.03	0.95–1.10	0.519
HIV-DNA (continuous)	1.01	1.00–1.02	0.003

Abbreviations: INI integrase inhibitors, NRTIs nucleoside reverse transcriptase inhibitors, NNRTIs non-nucleoside reverse transcriptase inhibitors, PIs protease inhibitors, HCV hepatitis C virus, HBV Hepatitis B virus, sCD14 soluble CD14, IL-6 interleukin- 6, TNF-α tumor necrosis factor α
^aProportional odds ratio. For example, concerning the variable “gender”, this is the proportional odds ratio of comparing females to males on viral load pattern level given that the other variables are held constant. For females, the odds of LLV vs. combined RV and TND are 1.22 times greater than for males. Likewise, the odds of the combined categories of LLV and RV vs. TND is 1.22 times greater for females compared to males, given the other variables are held constant in the model

ISSN: 1471-2334